Regenerative Medical Technology (RMTG) Non Operating Income (2023 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Non Operating Income of -$1.1 million for Q1 2026, down 23.58% year-over-year from -$1.4 million in Q1 2025, and down 1.79% quarter-over-quarter from -$1.1 million in Q4 2025.
Regenerative Medical Technology (RMTG) Non Operating Income (2023 - 2026) Analysis & Trends
Regenerative Medical Technology's Non Operating Income history runs 4 years deep, the most recent figure standing at -$1.1 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 23.58% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at -$7.2 million (down 52.81% YoY), while the FY2025 annual figure was -$6.9 million, down 23.05% from the prior year.
- Non Operating Income for Q1 2026 stood at -$1.1 million, down from -$1.1 million in the prior quarter.
- The five-year high for Non Operating Income was -$120926.0 in Q4 2023, with the low at -$5.8 million in Q3 2023.
- The 4-year median for Non Operating Income is -$1.1 million (2025), against an average of -$1.8 million.
- Peak annual rise in Non Operating Income reached 84.32% in 2024, while the deepest fall reached 742.5% in 2024.
- Regenerative Medical Technology's Non Operating Income stood at -$120926.0 in 2023, then tumbled by 742.5% to -$1.0 million in 2024, then slipped by 6.65% to -$1.1 million in 2025, then decreased by 1.79% to -$1.1 million in 2026.
- Business Quant data shows RMTG's Non Operating Income at -$1.1 million in Q1 2026, -$1.1 million in Q4 2025, and -$3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | -1.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.11 Mn |
| Dec 31, 2025 | -1.09 Mn |
| Sep 30, 2025 | -3.91 Mn |
| Jun 30, 2025 | -1.06 Mn |
| Mar 31, 2025 | -894,999.00 |
| Dec 31, 2024 | -1.02 Mn |
| Sep 30, 2024 | -906,794.00 |
| Jun 30, 2024 | -1.86 Mn |
| Mar 31, 2024 | -1.86 Mn |
| Dec 31, 2023 | -120,926.00 |
| Sep 30, 2023 | -5.78 Mn |